Trial Profile
A 2 Year Randomized, Single-masked, Multicenter, Controlled Phase IIIb Trial Assessing the Efficacy and Safety of 0.5 mg Ranibizumab in Two "Treat and Extend" Treatment Algorithms vs. 0.5 mg Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms RETAIN
- Sponsors Novartis; Novartis Pharmaceuticals
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2013 Planned end date changed from 1 May 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.